Urachal cancer

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Urachal cancer
File:Urachal carcinoma - high mag.jpg
Micrograph of urachal carcinoma (right of image) and non-malignant urothelium (left of image). H&E stain.
Classification and external resources
Specialty Lua error in Module:Wikidata at line 446: attempt to index field 'wikibase' (a nil value).
eMedicine radio/727
Patient UK Urachal cancer
[[[d:Lua error in Module:Wikidata at line 863: attempt to index field 'wikibase' (a nil value).|edit on Wikidata]]]

Urachal cancer is a rare form of cancer that can sometimes involve the bladder, but does not arise from the urothelium and is therefore not bladder cancer in the usual sense. The disease arises from malignant transformation of rests of enteric epithelium in the urachus, an embryonic structure located between dome of the bladder and the umbilicus. Urachal cancer can occur at any site along the urachal tract. The most common locations are the umbilicus and the dome of the bladder. Urachal cancer was first described in 1863 by Hue and Jaequin.

Symptoms

Urachal cancer can exist for some years without any symptoms. Sometimes the first symptom is haematuria (blood in the urine), but this can have many other causes.

Diagnosis

The diagnosis of Urachal cancer can be difficult, and unfortunately there are no specific symptoms. The CT[clarification needed] appearance is quite characteristic. Not only does it often progress silently, but because the most common presentation involves blood in the urine, it is commonly confused with conventional bladder cancer initially.

Treatment

Urachal cancer does not seem to respond to the usual chemotherapy treatments for bladder cancer, but recently there seems to have been more success using chemotherapy regimens used for bowel cancer. Surgery is the mainstay of treatment for clinically localized disease, and has been shown to be more successful when the entire urachal remnant and bladder dome are taken "en bloc."

Prognosis

The prognosis for patients with metastatic or recurrent disease is poor, with median survivals reported in the range of 1 to 2 years. There are anecdotal reports of long-term survival with bowel cancer regimens, but these are clearly exceptional.

References

Lua error in package.lua at line 80: module 'strict' not found.

External links